Aurinia Pharmaceuticals Inc – Analysts at Svb Leerink lifted their Q3 2019 income for each offer (EPS) gauges for Aurinia Pharmaceuticals in an exploration note issued to financial specialists on Wednesday, August seventh, as indicated by Zacks Investment Research.
Svb Leerink examiner J. Schwartz now expects that the organization will procure ($0.25) per share for the quarter, up from their earlier gauge of ($0.27). Svb Leerink likewise issued appraisals for Aurinia Pharmaceuticals’ Q4 2019 profit at ($0.29) EPS, FY2019 income at ($0.96) EPS, FY2020 profit at ($1.45) EPS and FY2021 income at ($0.72) EPS.
Aurinia Pharmaceuticals last declared its quarterly profit information on Tuesday, August sixth. The organization detailed C($0.23) income per share for the quarter, missing the Zacks’ accord gauge of C($0.20) by C($0.03). The business had income of C$0.04 million during the quarter, contrasted with the accord gauge of C$0.07 million.
AUP stock opened at C$7.85 on Friday. The stock’s multi day moving normal cost is C$8.19 and its multi day moving normal cost is C$8.48. The organization has an obligation to-value proportion of 0.33, a snappy proportion of 18.05 and a present proportion of 18.98.
The firm has a market top of $714.15 million and a P/E proportion of – 11.26. Aurinia Pharmaceuticals has a 1 year low of C$6.61 and a 1 year high of C$10.47.
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical organization, takes part in the examination, improvement, and commercialization of helpful medications for the treatment of immune system sicknesses in Canada, the United States, China, and Switzerland.
The organization is creating voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye disorder, and central segmental glomerulosclerosis.